BRIEF published on 08/08/2025 at 02:20, 8 months 30 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 8 months 30 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 10 months 12 days ago CureVac publie les résultats de son assemblée générale annuelle CureVac Nominations Au Conseil D'administration Commissaires Aux Comptes Technologie De L'ARNm Assemblée Annuelle
BRIEF published on 06/24/2025 at 22:14, 10 months 12 days ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 10 months 12 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
BRIEF published on 05/20/2025 at 13:05, 11 months 17 days ago CureVac Reports Q1 2025 Financials and Business Developments Financial Results Revenue Patents Oncology Pipeline R&D Developments
BRIEF published on 05/20/2025 at 13:05, 11 months 17 days ago CureVac publie ses résultats financiers et ses développements commerciaux pour le premier trimestre 2025 Résultats Financiers Brevets Revenu Pipeline En Oncologie Développements En R&D
PRESS RELEASE published on 05/20/2025 at 13:00, 11 months 18 days ago CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates CureVac announces financial results for Q1 2025 and updates on lung cancer and glioblastoma trials, urinary tract infection vaccine, and mRNA patents. Cash position strong at €438.3 million Financial Results Oncology Pipeline CureVac Q1 2025 MRNA Patents
BRIEF published on 05/15/2025 at 22:15, 11 months 22 days ago CureVac Gains Favorable Patent Decision Against BioNTech BioNTech MRNA Technology CureVac Patent Litigation European Patent Office
BRIEF published on 05/15/2025 at 22:15, 11 months 22 days ago CureVac obtient une décision favorable en matière de brevets contre BioNTech BioNTech CureVac Technologie De L'ARNm Office Européen Des Brevets Litiges En Matière De Brevets
Published on 05/07/2026 at 13:00, 3 minutes ago Eagle Plains Expands George Lake Deposit Mineralization, Reports 3.48% Zn+Pb over 45.1m in Step-out Drilling
Published on 05/07/2026 at 11:00, 2 hours 3 minutes ago Kingfisher Metals Announces Fully Funded 2026 Exploration Program
Published on 05/07/2026 at 09:05, 3 hours 58 minutes ago Nano One Appoints Jason Zandberg as Director of Capital Markets
Published on 05/07/2026 at 05:40, 7 hours 23 minutes ago New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 11 hours 3 minutes ago Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/07/2026 at 12:51, 12 minutes ago Original-Research: Zalando SE (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 05/07/2026 at 12:42, 20 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 05/07/2026 at 12:30, 33 minutes ago Multi Investment accelerates its diversification strategy following a CHF 480 million capital raise
Published on 05/07/2026 at 12:30, 33 minutes ago CTS EVENTIM: Unipol Dome Now Open – New Arena Sets Benchmark for Live Entertainment and Sports in Italy
Published on 05/07/2026 at 12:27, 36 minutes ago Original-Research: init innovation in traffic systems SE (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 05/07/2026 at 07:43, 5 hours 20 minutes ago ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 19 hours 3 minutes ago Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 19 hours 3 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 19 hours 3 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
